Neurocrine officer files 2,311-share sale notice

An NBIX officer filed a Rule 144 notice covering 2,311 common shares valued at $361,024.42 for potential sale on September 14, 2026.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) has a notice on file under Rule 144 for a potential sale of its common stock by officer Matthew C. Abernethy. The filing covers 2,311 shares of common stock, with an aggregate market value of $361,024.42, and references an intended sale date of September 14, 2026 on NASDAQ. The shares are tied to Performance Stock Units that were acquired from the issuer.

Key Figures

Shares covered: 2,311 shares Aggregate market value: $361,024.42 Referenced sale date: September 14, 2026

3 metrics

Shares covered 2,311 shares Common stock covered by the Rule 144 notice

Aggregate market value $361,024.42 Value of 2,311 NBIX shares referenced in the Form 144

Referenced sale date September 14, 2026 Date listed for the potential sale of the covered shares

Key Terms

Rule 144, Performance Stock Units, Aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Performance Stock Units financial

"Common | 09/14/2026 | Performance Stock Units | Issuer"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Aggregate market value financial

"Common ... | 2311 | 361024.42 | ..."

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for NBIX?

It discloses that officer Matthew C. Abernethy filed a Rule 144 notice for the potential sale of 2,311 shares of NEUROCRINE BIOSCIENCES INC common stock, with an aggregate market value of $361,024.42, referencing an intended sale date of September 14, 2026.

How many NBIX shares are covered by Matthew C. Abernethy’s Form 144?

The Form 144 covers 2,311 shares of NEUROCRINE BIOSCIENCES INC common stock, associated with Performance Stock Units acquired from the issuer and referenced for potential sale on September 14, 2026.

What is the aggregate market value of NBIX shares in this Form 144 filing?

The notice states an aggregate market value of $361,024.42 for the 2,311 NEUROCRINE BIOSCIENCES INC common shares covered by the potential Rule 144 sale.

When are the NBIX shares in this Form 144 referenced for potential sale?

The shares are referenced for potential sale on September 14, 2026. The Form 144 lists this date both in the securities information and in the section describing the securities to be sold.

What type of equity award underlies the NBIX shares in this Form 144?

The filing states that the 2,311 NEUROCRINE BIOSCIENCES INC common shares relate to Performance Stock Units acquired from the issuer, which are the source of the securities covered by the notice.

On which market is the NBIX stock in this Form 144 expected to trade?

The Form 144 identifies NASDAQ as the market for the NEUROCRINE BIOSCIENCES INC common stock covered by the potential Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:58 PM Accepted by SEC EDGAR 09/14/2026 - 04:49 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001724097
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NEUROCRINE BIOSCIENCES INC
SEC File Number	000-22705
Address of Issuer	6027 Edgewood Bend Court San Diego CALIFORNIA 92130
Phone	8586177600
Name of Person for Whose Account the Securities are To Be Sold	MATTHEW C ABERNETHY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2311	361024.42	101649181	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/14/2026	Performance Stock Units	Issuer			2311	09/14/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Matthew C. Abernethy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)